Leukemia & lymphomaHumansHematologic NeoplasmsHealthcare DisparitiesPatient SelectionClinical Trials as Topic
Reporting and enrollment disparities in hematologic malignancy trials between 2000-2023.
Inna Y Gong, Bahar Rafinejad-Farahani, Haris Majeed, Mark J Soto, Amit Oza, Tom Ehrlich, Holly Fernandez Lynch, Carmen E Guerra, Aisha Lofters, Joseph M Unger, Rena M Conti, Meredith Rosenthal, Danielle Rodin
Published: 202610.1080/10428194.2025.2579735
Abstract
Despite initiatives to enhance diversity in clinical trials (CTs), disparities persist in hematologic malignancy (HM) studies. We reviewed 1,230 US-based phase II-III HM CTs (2000-2023) including 149,434 participants and compared enrollment to SEER b…
Preview only. Read the full abstract at the source